RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
 Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Sep 15, 2017 - 4:49:58 AM
Research Article
Latest Research Channel

subscribe to Latest Research newsletter
Latest Research

   EMAIL   |   PRINT
Nasal spray vaccines more effective against flu

Apr 11, 2011 - 4:00:00 AM

Professor Metzger from Albany Medical College, New York explains the significance of the findings. Infectious agents still account for around 25% of deaths worldwide and the major killers are acute respiratory infections. However, it is difficult to induce immunity at the site of entry and so standard vaccines are only partially protective, he said. Intranasal vaccination gets around this problem by inducing immunity in the pulmonary passage. This prevents initial infection as well as systemic complications. Up until now, nasal vaccination has only resulted in sufficient immune responses for very specific types of vaccine. We now have evidence that this method could work for a wide range of vaccines when IL-12 is included in formulation, said Professor Metzger.


 
[RxPG] Nasal vaccines that effectively protect against flu, pneumonia and even bioterrorism agents such as Yersinia pestis that causes the plague, could soon be a possibility, according to research presented at the Society for General Microbiology's Spring Conference in Harrogate. Professor Dennis Metzger describes how including a natural immune chemical with standard vaccines can boost their protective effect when delivered through the nose.

The respiratory tract is a major entry site for various viral and bacterial pathogens. However there are few approved vaccines that can provide optimal protection against them due to the low immune response at muscosal surfaces such as the nasal passage.

Combining standard vaccines for respiratory pathogens with the immune chemical, interleukin-12 (IL-12) and delivering them intranasally to mice has been shown to induce high levels of protection. Vaccines against various respiratory pathogens were tested, including influenza virus, pneumococcal bacteria and Yersinia pestis - a Category A Biothreat. IL-12 is a natural immune chemical, known as a cytokine. It is a powerful stimulator of the immune response through its interactions with other immune chemicals and the white blood cells that produce them.

Professor Metzger from Albany Medical College, New York explains the significance of the findings. Infectious agents still account for around 25% of deaths worldwide and the major killers are acute respiratory infections. However, it is difficult to induce immunity at the site of entry and so standard vaccines are only partially protective, he said. Intranasal vaccination gets around this problem by inducing immunity in the pulmonary passage. This prevents initial infection as well as systemic complications. Up until now, nasal vaccination has only resulted in sufficient immune responses for very specific types of vaccine. We now have evidence that this method could work for a wide range of vaccines when IL-12 is included in formulation, said Professor Metzger.

Nasal vaccines could have a number of other advantages over vaccines that must be injected. Vaccination via a nasal spray is a non-invasive procedure that is easier than administering vaccines by injection. In addition our results have shown that antibodies induced by intranasal vaccination are effective not only in preventing infection but can also protect the pulmonary tract in a therapeutic manner after pathogen exposure, explained Professor Metzger. In the case of a bioterrorism threat or an influenza pandemic, this is significant. The next step is to perform clinical trials to determine whether including IL-12 with intranasal vaccines are effective in the human population.




Advertise in this space for $10 per month. Contact us today.


Related Latest Research News


Subscribe to Latest Research Newsletter

Enter your email address:


 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

Online ACLS Certification

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)